Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.47 |
| ▸ | FABP3 | P05413 | 3/20 | 0.44 |
| ▸ | FABP4 | P15090 | 3/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | CMKLR1 | Q99788 | 6/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131835 | 1.00 | MDM2 (0.47) | MDM2FABP3FABP4BCL2MCL1 | |
| SCHEMBL1132021 | 0.86 | PTGS2 (0.40) | FABP3FABP4CMKLR1 | |
| SCHEMBL1132134 | 0.86 | MDM2 (0.63) | MDM2FABP3FABP4BCL2MCL1 | |
| SCHEMBL1132019 | 0.86 | PTGS2 (0.40) | FABP3FABP4CMKLR1 | |
| SCHEMBL1131946 | 0.84 | FAAH (0.54) | MDM2FABP3FABP4BCL2MCL1 | |
| SCHEMBL1131277 | 0.84 | MDM2 (0.48) | MDM2FABP3FABP4BCL2MCL1 | |
| SCHEMBL1131567 | 0.82 | CMKLR1 (0.39) | FABP3FABP4CMKLR1 | |
| SCHEMBL1131977 | 0.80 | FABP3 (0.34) | MDM2FABP3FABP4BCL2MCL1 | |
| SCHEMBL1131417 | 0.80 | ALOX5 (0.43) | MCL1BTKSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1131691 | 0.80 | ALOX5 (0.43) | MCL1BTKSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | claimed |
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |